The Cardiotoxicity Protection Of Dexrazoxane On Epirubicin

Objective:To observe the cardiotoxicity protective effect of dexrazoxane (Dexrazoxane, DEX) on epirubicin (EPI) adjuvant chemotherapy in breast cancer patients.Method:Randomly assigned women with breast cancer treated in our hospital were divided into observation group and control group, and all patients were treated with EPI-based adjuvant chemotherapy. The observation group was used DEX (DEX:EPI=10:1) at the1st EPI application. The electrocardiogram (ECG), cardiac troponin T (cTnt) and left ventricular ejection fraction (LVEF) were used to assessment of cardiac functional status at before treatment, paragraphs1and3cycles, the treatment is completed, after treatment six months and after treatment one year, also observe the non-cardiac toxicity side effect of chemotherapy.Result:Two groups in age, weight, ECOG score and staging were no statistically significant difference (P>0.05). In the control group the cTnt level was siginificantly increased after one cycle of treatment, highest at the end of the treatment and maintain of high level until after treatment1year; in the observation group the cTnt level was statistically significant lower than control group during the treatment and after treatment. The LVEF in the two group were not statistically significant level (P>0.05). The non-cardiac side effects were no differences in both groups.Conclusion:Epirubicin-based chemotherapy causes an early increase of the cTnt and abnormal electrocardiographic pattern, which is attenuated by dexrazoxane prevented. Threrfore, dexrazoxane can reduce the cardiac toxicity side effects in patients treated with epiurubicin chemotherapy.